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The blood-brain barrier supplies brain tissues with nutrients and filters certain compounds
from the brain back to the bloodstream. In several neurodegenerative diseases, including
Parkinson’s disease (PD), there are disruptions of the blood-brain barrier. Cerebrospinal
fluid (CSF) has been widely investigated in PD and in other parkinsonian syndromes with
the aim of establishing useful biomarkers for an accurate differential diagnosis among
these syndromes. This review article summarizes the studies reported on CSF levels of
many potential biomarkers of PD. The most consistent findings are: (a) the possible role
of CSF urate on the progression of the disease; (b) the possible relations of CSF total
tau and phosphotau protein with the progression of PD and with the preservation of
cognitive function in PD patients; (c) the possible value of CSF beta-amyloid 1-42 as a
useful marker of further cognitive decline in PD patients, and (d) the potential usefulness
of CSF neurofilament (NFL) protein levels in the differential diagnosis between PD and
other parkinsonian syndromes. Future multicentric, longitudinal, prospective studies with
long-term follow-up and neuropathological confirmation would be useful in establishing
appropriate biomarkers for PD.
Keywords: Parkinson’s disease, cerebrospinal fluid, biological markers, neurotransmitters, oxidative stress, tau
protein, alpha-synuclein, beta-amyloid
INTRODUCTION
The diagnosis of Parkinson’s disease (PD) in live patients is fun-
damentally clinical, and is based on the presence of its cardinal
signs (rest tremor, rigidity, bradykinesia, and postural instability),
and the absence of atypical data for idiopathic PD. The final con-
firmation of the diagnosis is made by post-mortem neuropatho-
logical analysis. To date, there are no definitive biomarkers to
make an accurate differential diagnosis with other parkinsonian
syndromes.
Because the cerebrospinal fluid (CSF) is in close contact with
the extracellular space of the brain, it is believed that many of
the biochemical modifications in the brain should be reflected
in the CSF. Therefore, CSF has been widely investigated in PD
and in other parkinsonian syndromes with the aim of acquiring
knowledge on the pathogenesis of this disease. This article sum-
marizes the data on analyses performed in the CSF of patients
diagnosed with PD compared with controls, with regard to: (1)
concentrations of neurotransmitters (mainly monoamines and
their metabolites), neuromodulators, and related substances as
possible biological markers of the disease itself or its complica-
tions; (2) concentrations of endogenous neurotoxins; (3) status
of oxidative stress markers or substances which could be related
with the induction of oxidative stress or with “neuroprotection”
against it; (4) status of inflammation and immunological mark-
ers, neurotrophic and growth factors, and (5) concentrations of
proteins related with the pathogenesis of PD or other compounds.
The aim of this review is to provide an extensive descriptive
overview of studies published on this issue (including references
to many reports in the last six decades which have historical
interest).
SEARCH STRATEGY
References for this review were identified by searching in PubMed
from 1966 until June 20, 2014. The term “Parkinson’s disease” was
crossed with “cerebrospinal fluid” and “blood brain barrier,” and
the related references were selected. Table 1 summarizes a clas-
sification of the diverse types of compounds which have been
analyzed in the CSF of PD patients in accordance with the search.
NEUROTRANSMITTERS, NEUROMODULATORS, AND
RELATED SUBSTANCES
DOPAMINE METABOLITES
Because the main neurochemical finding in PD is the depletion of
dopamine (DA) in the nigroestriatal system (Benito-León et al.,
2008), it is to be expected that the CSF concentrations of the
main metabolites of DA, dihydroxyphenyl-acetyc acid (DOPAC)
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Table 1 | Relation and classification of compounds measured in CSF of PD.
(A) Neurotransmitters, neuromodulators, and related substances
(1) Dopamine (DA) metabolites: dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), 3-orthomethylDOPA (3-OMD)
(2) Serotonin (5-hydroxytryptamine or 5-HT) metabolites or precursors: 5-hydroxytryptophan (5-HTP), 5-hydroxyindoleacetic acid (5-HIAA),
kynurenine, 3-hydroxykynurenine
(3) Noradrenalin (norepinephrine or NE) metabolites or precursors: 3-methoxy-4-hydroxy-phenylethylenglycol (MHPG),
dopamine-beta-hydroxylase (DBH)
(4) Acetylcholine (Ach) and related substances: choline, acetylcholine-esterase (AchE), butiryl-cholin-esterase (BchE)
(5) Neurotransmitter amino acids: gamma-amino butyric acid (GABA), glutamate, aspartate, glycine
(6) Neuropeptides: substantia P (SP), cholecystokinin-8 (CCK-8), met-enkephalin (MET-ENK), leu-enkephalin (LEU-ENK), dynorphin A(1-8),
somatostatin, neuropeptide Y (NPY), beta-endorphin, arginine-vasopressine (AVP), vasoactive intestinal peptide (VIP), delta sleep-inducing
peptide (DSIP), alpha-melanocyte-stimulating hormone-like, diazepam-binding inhibitor, neurokinin A, corticotropin-releasing hormone
(CRH), adrenocorticotropin hormone (ACTH), beta-lipotropine, angiotensin, chromogranins A and B, secretogranin II, orexin-A/hypocretin-1
(7) Other neurotransmitters: endogenous cannabinoids, β-phenylethylamine
(8) Cyclic nucleotides: cyclic adenosine 3′5′ monophosphate (cAMP), cyclic guanosine 3′5′ monophosphate (cGMP)
(9) Biopterin derivatives and other cofactors
(B) Endogenous neurotoxins
(1) Tetrahydroisoquinolin (TIQ) derivatives: 2-methyl-6,7-dihydroxy1,2,3,4-TIQ (2-MDTIQ), 1-MDTIQ (salsolinol). 1-benzyl-1,2,3,4-TIQ
(2) β-carbolinium cations (BC+s)
(C) Oxidative stress markers
(1) Lipid peroxidation markers: Malonyl-dialdehyde (MDA) (E)-4-hydroxynonenal (HNE) Low density lipoprotein (LDL) oxidation products Schiff
bases, conjugated dienes, oxidized proteins, and aldehyde polymers
(2) DNA oxidation markers: 8′-hydroxy-2′deoxyguanine (8-OHdG) 8-hydrosyguanosine (8-OHG) 8-OHdG/8-OHG ratio
(3) Transition metals and related proteins: iron, ferritin, transferring, copper, cerulopasmin, ferroxidase, manganese, zinc
(4) Other metals: selenium, chromium, magnesium, calcium, aluminum, silicon, cobalt, tin, lead, barium, bismuth, cadmium, mercury,
molibdenum, nichel, antimony, strontium, thallium, vanadium, wolfram, and zirconium
(D) Inflamatory and immunological markers
(1) Inteleukins (IL)
(2) Tumor necrosis alpha (TNF-α)
(3) Other: leukotrienes. α-1-antichymotrypsin
(E) Growth and neurotrophic factors
(1) Brain-derived neurotrophic factor (BDNF)
(2) Transforming Growth Factors: TGF-α, TGF-β1, TGF-β2
(3) Insulin-like growth factor-1 (IGF-1) and IGF-binding proteins (IGFBPs)
(4) Neuroregulins (Epidermal Growth Factor or EGF family)
(F) Proteins involved in the pathogenesis of PD
(1) Microtubular-Associated Protein Tau (MAPT)
(2) Alpha-synuclein
(3) Amiloyd beta
(4) Neurofilament proteins
(5) Other proteins: DJ-1, UCH-L1
(G) Other compounds
and homovanillic acid (HVA), should be decreased. Indeed,
many classical studies have shown variable degrees of decrease
in the CSF HVA levels of PD patients compared with controls
(Bernheimer et al., 1966; Guldberg et al., 1967; Johansson and
Roos, 1967; Olsson and Roos, 1968; Gottfries et al., 1969; Curzon
et al., 1970; van Woert and Bowers, 1970; Godwin-Austen et al.,
1971; Mones et al., 1972; Papeschi et al., 1972; Pullar et al., 1972;
Cox et al., 1973; Voto Bernales et al., 1973; Weiner and Klawans,
1973; Granerus et al., 1974; Davidson et al., 1977; Tabaddor et al.,
1978; Lovenberg et al., 1979; Cunha et al., 1983; Mann et al., 1983;
Cramer et al., 1984; Mena et al., 1984; Pezzoli et al., 1984; Burns
et al., 1985; Gibson et al., 1985; Jolkkonen et al., 1986; Liu, 1989;
Hartikainen et al., 1992; Strittmatter and Cramer, 1992; Chia
et al., 1993; Mashige et al., 1994; Eldrup et al., 1995; Cheng et al.,
1996; Strittmatter et al., 1996; Kanemaru et al., 1998; Goldstein
et al., 2008). Engelborghs et al. (2003) reported normal CSF DA
and HVA, and decreased DOPAC levels. González-Quevedo et al.
(1993) described normal CSF HVA levels, Espino et al. (1994)
Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 369 | 2
Jiménez-Jiménez et al. Cerebrospinal fluid in Parkinson’s disease
found decreased HVA only in advanced but not in early PD,
Parkinson Study Group DATATOP Investigators found normal
levels in early PD (LeWitt et al., 2011). Zubenko et al. (1986)
described a non-significant trend toward decreased CSF HVA
levels in demented PD patients compared with controls. Tohgi
et al. (1993a) found correlation of CSF DA and HVA levels with
akinesia and freezing of gait.
Although levodopa treatment usually increases CSF HVA lev-
els according to the majority of studies, this is not related
with clinical improvement, with some exceptions (Durso et al.,
1989), and pre-treatment CSF HVA levels does not predict lev-
odopa response (Weiner et al., 1969; Chase, 1970; Curzon et al.,
1970; Bertler et al., 1971; Casati et al., 1973; Cox et al., 1973;
Mones, 1973; Weiner and Klawans, 1973; Granerus et al., 1974;
Davidson et al., 1977; Liu, 1989; Nishi et al., 1989; Strittmatter
et al., 1996; Antkiewicz-Michaluk et al., 1997; Durso et al.,
1997; Krygowska-Wajs et al., 1997), except in one study which
described an association between relatively high pre-treatment
CSF HVA levels and a better response to levodopa (Gumpert
et al., 1973). One study failed to show changes in ventricular
CSF HVA levels after a single acute administration of levodopa
(Moussa et al., 1992). On the other hand, dopamine agonists
such as piribedil and bromocriptine decreased significantly both
the basal level (McLellan et al., 1975; Rinne et al., 1977) and
probenecid-induced accumulations of HVA in CSF (Rinne et al.,
1975, 1977), indicating that the drugs reduced the turnover of
endogenous dopamine. Amantadine did not change HVA levels
(Cox et al., 1973). Tetrahydrobiopterin (Dissing et al., 1989) and
L-threo-3,4-dihydroxyphenylserine (precursor or noraderenalin
or norepinephrine –NE) (Maruyama et al., 1994) increased CSF
HVA levels in PD patients, but to a lesser extent than levodopa.
Friedman et al. (Friedman, 1985) reported an HVA/5-HIAA
ratio in PD patients who developed levodopa-induced dyskine-
sias (LID) which was significantly higher than in PD patients
under levodopa therapy and in controls, but Lunardi et al.
(2009) found similar HVA/DA ratios in patients with and with-
out LID. CSF DA, levodopa, and HVA levels were similar in PD
patients treated with levodopa with wearing-off motor fluctu-
ations to those without this complication of levodopa therapy,
while CSF 3-ortho-methyldopa (3-OMD) levels were higher in
the fluctuating patients (Tohgi et al., 1991a). CSF DOPAC and
HVA were similar in PD patients with and without depres-
sion (Kuhn et al., 1996a), and in patients with major depres-
sion with PD than in those without PD (Pålhagen et al.,
2010). CSF HVA levels were correlated with striatal uptake
in PD patients measured with PET imaging with carbon-11-
labeled 2β-carbomethoxy-3β-(4-fluorophenyl)-tropane (11C-FT)
(Ishibashi et al., 2010).
Tohgi et al. (1991b, 1997) found a significant increase in
tyrosine, and a significant decrease in CSF levodopa, DA, and 3-
OMD in PD patients, which was related with levodopa dosage,
and described an additional decrease in 3-OMD in subjects
treated with tolcapone (Tohgi et al., 1995a). Other authors
reported increased CSF 3-OMD related with levodopa therapy
(Antkiewicz-Michaluk et al., 1997; Krygowska-Wajs et al., 1997).
On the other hand, Chia et al. (1993) found normal CSF 3-
OMD concentrations. Moser et al. (1996) described increased
CSF levodopa/3-OMD ratio in PD patients with hallucinations.
Iacono et al. (1997) found similar HVA levels in PD patients
with postural instability and gait disorders to PD patients without
these symptoms.
Although many of the studies of DA metabolites were per-
formed on patients with different types of parkinsonism, with
different degrees of severity, and the fact that many of these
studies were made using small sample sizes, there is a general
consensus that CSF HVA levels are decreased in untreated PD
patients and rise after levodopa therapy starts (decreased HVA
may not be present in early stages of PD). It is to be expected
that low CSF HVA levels should be a reflection of DA depletion
in the nigroestriatal system. However, CSF DA metabolite levels
are not useful to distinguish between different parkinsonian syn-
dromes and could be normal in early stages of the disease. To our
knowledge, no studies have been published regarding the corre-
lation of CSF DA metabolite levels and brain DA levels, although
the observation of a correlation between CSF HVA levels and stri-
atal uptake of DAmarkers in PET imaging (Ishibashi et al., 2010),
suggests this correlation.
SEROTONIN (5-HYDROXYTRYPTAMINE OR 5-HT) METABOLITES
Several studies have described neuronal loss, and presence of
Lewy body in serotonergic raphe nuclei in PD patients (Benito-
León et al., 2008). Tohgi et al. (1993b,c, 1997) reported a 15–20%
reduction of CSF 5-HT, tryptophan (precursor of 5-HT), kynure-
nine and 3-hydroxykynurenine (metabolites of tryptophan) levels
in PD patients. CSF 5-HT levels showed a negative correlation
with the severity of bradykinesia, rigidity and freezing of the gait,
and decreased after levodopa therapy. This group also found a
correlation between CSF 5-HIAA levels and akinesia and freezing
of gait (Tohgi et al., 1993a). In contrast, Engelborghs et al. (2003)
described increased 5-HT levels. LeWitt et al. (2013) described
increased CSF 3-hydroxykynurenine levels, and Widner et al.
(2002) described an increased CSF kynurenine/tryptophan ratio
in PD patients.
Several studies have shown reduced CSF levels of 5-
hydroxyindoleacetic acid (5-HIAA), themainmetabolite of 5-HT,
in PD patients (Guldberg et al., 1967; Johansson and Roos, 1967,
1971; Olsson and Roos, 1968; Gottfries et al., 1969; Chase, 1970;
Rinne and Sonninen, 1972; Rinne et al., 1973; Davidson et al.,
1977; Mayeux et al., 1984, 1986, 1988; Kostic´ et al., 1987; Tohgi
et al., 1993c, 1997; Mashige et al., 1994; Strittmatter et al., 1996;
Engelborghs et al., 2003). Other authors report normal CSF 5-
HIAA levels (Papeschi et al., 1970, 1972; Godwin-Austen et al.,
1971; Granerus et al., 1974; Davidson et al., 1977; Tabaddor et al.,
1978; Cramer et al., 1984; Burns et al., 1985; Chia et al., 1993;
González-Quevedo et al., 1993; Volicer et al., 1985; Fukuda et al.,
1989). Liu et al. (1999) described lower ventricular CSF 5-HIAA
levels in patients with rigid-akinetic PD than in patients with
tremoric PD, and a negative correlation between CSF 5-HIAA
levels and PD severity.
CSF 5-HIAA levels seem to be unchanged by therapy with
levodopa (Godwin-Austen et al., 1971; Davidson et al., 1977),
bromocriptine (Gumpert et al., 1973), or piribedil (Gumpert
et al., 1973), or were found decreased by levodopa ther-
apy (Casati et al., 1973). Gumpert et al. (1973) described an
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association between relatively low pre-treatment CSF 5-HIAA
levels with a good response to levodopa, while Davidson et al.
(1977) reported this association with higher CSF 5-HIAA lev-
els, and others found no such relation (Granerus et al., 1974).
Tetrahydrobiopterin increased (Dissing et al., 1989), and L-threo-
3,4-dihydroxyphenylserine decreased (Maruyama et al., 1994)
CSF 5-HIAA levels.
Some authors have described decreased CSF 5-HIAA (Mayeux
et al., 1984, 1986, 1988; Mena et al., 1984; Kostic´ et al., 1987) and
5-HT levels (Mena et al., 1984) in PD patients with depression,
while others have described normal CSF 5-HIAA in depressed
PD patients (Granerus et al., 1974; Kuhn et al., 1996a), and oth-
ers still have reported similar CSF 5-HIAA levels in patients with
major depression with PD tothose without PD (Pålhagen et al.,
2010). Moser et al. (1996) described increased CSF 5-HIAA in PD
patients with hallucinations. Iacono et al. (1997) found higher
CSF 5-HT and 5-HIAA and lower 5-HTP levels in PD patients
with postural instability and gait disorders than in PD patients
without these symptoms.
Studies on the correlation of CSF 5-HT metabolite levels and
brain 5-HT levels are lacking. The majority of studies report
results on CSF 5-HIAA levels, with the controversial results
based on short series of cohorts of patients with PD or other
parkinsonian syndromes. Current data do not lend support to
the role of CSF 5-HIAA as an unequivocal marker of depression
linked to PD.
NORADRENALIN (NOREPINEPHRINE OR NE) METABOLITES
Neurons containing NE in the brain, mainly in the dorsal nuclei
of vagus nerve, are involved in the degenerative process of PD
(Benito-León et al., 2008). CSF NE levels have been found nor-
mal (Turkka et al., 1987; Chia et al., 1993; Kuhn et al., 1996a;
Engelborghs et al., 2003) or decreased (Martignoni et al., 1992;
Eldrup et al., 1995) in PD patients. CSF levels of 3-methoxy-4-
hydroxy-phenylethyleneglycol (MHPG), the main metabolite of
NE, have been reported to be normal (Wilk and Mones, 1971;
Davidson et al., 1977; Mann et al., 1983; Mena et al., 1984;
Hartikainen et al., 1992; Martignoni et al., 1992; Chia et al.,
1993; González-Quevedo et al., 1993; Mashige et al., 1994; Kuhn
et al., 1996a; Engelborghs et al., 2003) or decreased (Granerus
et al., 1974) in PD patients. CSF MHPG levels do not increase
either after treatment with levodopa (Wilk and Mones, 1971;
Davidson et al., 1977) or with the NE precursor L-Threo-3,4-
dihydroxyphenylserine (L-threo-DOPS) (Yamamoto et al., 1986;
Teelken et al., 1989), while L-threo-DOPS increases CSF NE levels
(Tohgi et al., 1990, 1993d).
Several authors have described a negative correlation between
CSF MHPG levels and cognitive functioning (Mann et al., 1983)
and bradyphrenia (Mayeux et al., 1987) in PD patients, and oth-
ers have described a relationship between CSF NE levels with
severity of PD assessed by Hoehn & Yahr staging, akinesia scores,
and freezing of the gait (Tohgi et al., 1993a). Pålhagen et al.
reported decreased CSF MHPG levels in patients with major
depression with PD compared to those without PD (Pålhagen
et al., 2010).
CSF activity of dopamine-β-hydroxylase (DBH), an enzyme
involved in NE synthesis, has been found decreased in PD
patients when compared with controls (Matsui et al., 1981; Hurst
et al., 1985).
The normality of CSF MHPG levels found in nearly all studies
with PD or other parkinsonian syndromes indicates that this is
not a useful marker of PD. The correlation between CSF MHPG
and brain NE is unknown.
ACETYLCHOLINE (Ach) AND RELATED SUBSTANCES
CSF levels of Ach (Duvoisin and Dettbarn, 1967; Welch et al.,
1976; Yamada et al., 1996) and its precursor choline (Aquilonius
et al., 1972; Welch et al., 1976; Nasr et al., 1993) have been
reported to be similar in PD patients to controls with the excep-
tion of one study in which lower CSF choline levels were described
in PD patients (Manyam et al., 1990).
CSF activity of acetylcholine-esterase (AchE), the main
enzyme involved in Ach degradation, has been reported to be
similar in PD patients and controls (Jolkkonen et al., 1986;
Ruberg et al., 1986; Zubenko et al., 1986; Sirviö et al., 1987;
Yoshinaga et al., 1989; Manyam et al., 1990; Hartikainen et al.,
1992), although there are studies which have described increased
(Ruberg et al., 1986), decreased (Konings et al., 1995), or normal
activity (Zubenko et al., 1986; Sirviö et al., 1987) in demented
patients, and decreased activity only in those patients with the
most severe disease (Hartikainen et al., 1992).
CSF activity of butirylcholine-esterase (BchE) have been found
to be similar in PD patients and controls (Ruberg et al., 1986;
Sirviö et al., 1987), but increased in demented PD patients in a
single study (Ruberg et al., 1986). Data on CSF Ach and related
substances are scarce and based on short series of patients, and do
not permit valid conclusions.
GAMMA-AMINO BUTYRIC ACID (GABA) AND OTHER
NEUROTRANSMITTER AMINO ACIDS
CSF GABA levels in PD patients have been found to be decreased,
when compared with controls, by many authors (Lakke and
Teelken, 1976; Manyam et al., 1980, 1988; Kuroda et al., 1982;
Manyam, 1982; Teychenné et al., 1982; Kuroda, 1983; de Jong
et al., 1984; Araki et al., 1986; Tohgi et al., 1991c), while oth-
ers have found this value to be normal (Enna et al., 1977;
Abbott et al., 1982; Bonnet et al., 1987; Perschak et al., 1987;
Mally et al., 1997; Engelborghs et al., 2003) or even increased
(Jiménez-Jiménez et al., 1996). Manyam and Tremblay (1984)
found reduced CSF free GABA levels and normality of conju-
gated levels. Abbot et al. (Perschak et al., 1987) found decreased
CSF GABA levels in PD patients treated with levodopa, but not
in “de novo” PD patients, while other authors found decreased
CSF GABA in untreated PD patients (Manyam, 1982; de Jong
et al., 1984), with CSF GABA normal (de Jong et al., 1984; Tohgi
et al., 1991c) or slightly decreased (Manyam, 1982) in PD patients
under levodopa therapy, suggesting that levodopa increases CSF
levels. Teychenné et al. (1982) described low CSF GABA especially
in PD patients with poor response to therapy or suffering from
“on-off” motor fluctuations.
Normality of CSF glutamate levels has been reported by most
investigators (Van Sande et al., 1971; Gjessing et al., 1974; Lakke
and Teelken, 1976; Lakke et al., 1987; Perschak et al., 1987;
Espino et al., 1994; Jiménez-Jiménez et al., 1996; Kuiper et al.,
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2000), although 3 groups described decreased CSF glutamate lev-
els (Gründig and Gerstenbrand, 1980; Tohgi et al., 1991c; Mally
et al., 1997), while CSF glutamine (the main precursor of gluta-
mate) has been found to be normal (Gjessing et al., 1974; Lakke
and Teelken, 1976; Manyam et al., 1988; Jiménez-Jiménez et al.,
1996) or increased (Mally et al., 1997).
CSF aspartate levels have been reported as normal (Lakke
and Teelken, 1976; Manyam, 1982; Araki et al., 1986; Perschak
et al., 1987; Mally et al., 1997; Jiménez-Jiménez et al., 1996;
Engelborghs et al., 2003), except in the study by Tohgi et al.
(1991c) who reported decreased CSF aspartate; CSF asparagine
(the main metabolite of aspartate) has been found normal (Lakke
and Teelken, 1976; Manyam, 1982; Araki et al., 1986; Perschak
et al., 1987; Jiménez-Jiménez et al., 1996; Mally et al., 1997;
Engelborghs et al., 2003).
The results on CSF glycine levels have been reported as normal
by most investigators (Gjessing et al., 1974; Perschak et al., 1987;
Manyam et al., 1988; Jiménez-Jiménez et al., 1996; Mally et al.,
1997; Engelborghs et al., 2003), although two groups found them
increased (Lakke and Teelken, 1976; Araki et al., 1986; Lakke et al.,
1987), and another decreased (Tohgi et al., 1991c). In agreement
with Tohgi et al. (1991c), our group reported lower glycine levels
in untreated PD patients when compared with PD patients under
levodopa therapy or with controls (Jiménez-Jiménez et al., 1996).
Data regarding other (non-neurotransmitter) amino acids are
even more controversial. CSF levels of neutral and basic amino
acids have been reported to be both increased (Van Sande et al.,
1971; Lakke and Teelken, 1976; Lakke et al., 1987), and decreased
(Molina et al., 1997a). Two groups reported decreased (Molina
et al., 1997a; Engelborghs et al., 2003) and another increased CSF
levels of taurine (Lakke and Teelken, 1976; Araki et al., 1986;
Lakke et al., 1987). Ornithine, citruline, and arginine (implicated
in the urea cycle, and the two latter in the synthesis of nitric
oxide) have been found to be increased (Van Sande et al., 1971;
Lakke and Teelken, 1976; Lakke et al., 1987), normal (Kuiper
et al., 2000), or decreased (Molina et al., 1997a). Another group
described increased CSF levels of total homocysteine but normal
ones of free homocysteine in PD patients (Isobe et al., 2005), with
an additional increase after treatment with levodopa, while total
methionine levels decreased after this therapy (Isobe et al., 2010a).
In general, the results on CSF amino acid levels in PD patients
are inconclusive, because they might be influenced by selection
of study subjects, sample size, lack of adequate matching between
cases and controls in many studies, differences in antiparkinso-
nian therapy, and differences in study techniques, storage and
handling of the samples (Jiménez-Jiménez et al., 1996; Molina
et al., 1997a).
NEUROPEPTIDES
Neuropeptides modulate neuronal communication by acting on
cell surface receptors. Many of them are co-released with clas-
sical neurotransmitters. There have been reports of a number
of changes in the concentrations of several neuropeptides in
PD brain, which are mainly significant decreases in (Jiménez-
Jiménez, 1994): (a) met-enkephalin (MET-ENK), substantia P
(SP), and cholecystokinine 8 (CCK-8) in the substantia nigra;
(b) MET-ENK and leu-enkephalin (LEU-ENK) in the putamen
and globus pallidus; (c) MET-ENK in the ventral tegmental area;
(d) SP, somatostatin and neurotensin in the neocortex, and (e)
somatostatin and neurotensin in the hippocampus. It is likely that
many of these changes are related with dopaminergic deficit, and
the only clear relationship between a neuropeptide and a clinical
feature of PD is that of somatostatin with the presence of cog-
nitive impairment (Jiménez-Jiménez, 1994). Table 2 summarizes
the findings of classical studies on CSF neuropeptide levels in PD
patients. Most of these studies enrolled limited series of patients.
In recent years, there has been increased interest in the possible
role of orexin-A/hypocretin-1, a neuropeptide hormone impli-
cated in the pathogenesis of narcolepsia, on the development of
excessive daytime sleepiness in PD patients. Since the first report
by Drouot et al. (2003), who described decreased ventricular CSF
orexin levels in PD patients, which were related with the severity
of the disease, other authors have confirmed decreased CSF orexin
in PD (Fronczek et al., 2007; Asai et al., 2009) and in other neu-
rodegenerative parkinsonisms (Yasui et al., 2006), and the relation
of CSF orexin with severity of PD (Asai et al., 2009), and with the
presence of sleep attacks (Asai et al., 2009). In contrast, Compta
et al. (2009a) found no significant differences in CSF orexin lev-
els between demented PD patients, non-demented PD patients,
and healthy controls, and found no relation between CSF orexine
and Epworth sleepiness scale or Mini-Mental State Examination.
Drouot et al. (2011) found a lack of association between low ven-
tricular CSF orexin and sleepiness in PD, and a relation between
high levels of orexin-A in PD associated with loss of REM mus-
cle atonia (Bridoux et al., 2013), while Wienecke et al. (2012)
reported association between low CSF orexin levels and sleepi-
ness in PD. Finally, Pålhagen et al. (2010) described similar CSF
orexin levels in patients with major depression with or without
concomitant PD. The results regarding orexin A are controversial,
and await confirmation.
OTHER NEUROTRANSMITTERS
Pisani et al. (2005, 2010) found increased CSF levels of the
endogenous cannabinoid anandamide in untreated PD patients,
which were unrelated to the severity of the disease (Pisani
et al., 2005) and reversed by chronic dopaminergic replace-
ment (Pisani et al., 2010). Zhou et al. (1997) found decreased
CSF β-phenylethylamine (PEA) levels in PD patients which were
correlated negatively with Hoehn & Yahr stage.
CYCLIC NUCLEOTIDES
These compounds act as intracellular second messengers of neu-
rotransmitters or other compounds such as nitric oxide (NO).
The most important are cyclic adenosine 3′5′ monophosphate
(cAMP) and cyclic guanosine 3′5′ monophosphate (cGMP).
Belmaker et al. (1978) reported a 40–50% decrease of CSF cAMP
and an 80–90% decrease of CSF cGMP levels in PD patients who
were not related with levodopa therapy. Decreased CSF cAMP lev-
els in PD have also been reported in another study (Volicer et al.,
1986), while others found this value to be normal (Cramer et al.,
1973, 1984; Covickovic´-Sternic´ et al., 1987; Oeckl et al., 2012),
both in PD patients with and without dementia (Oeckl et al.,
2012). Four further studies described normal CSF cGMP levels
(Volicer et al., 1986; Covickovic´-Sternic´ et al., 1987; Ikeda et al.,
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Table 2 | Alterations in CSF neuropeptide levels in PD patients compared with controls.
Neuropeptide References PD patients/
Controls
Cerebrospinal fluid levels
Substantia P (SP) Pezzoli et al., 1984 12/10 Increased 5-fold
Cramer et al., 1989 15/9 Normal
Cramer et al., 1991 23/9 Decreased by 30% (controls were essential tremor patients)
Cholecystokinin-8
(CCK-8)
Lotstra et al., 1985 20/68 Decreased by 50%
Met-enkephalin
(MET-ENK)
Pezzoli et al., 1984 12/10 Increased 3-fold in PD patients with slight or moderate disability
(n = 6)
Yaksh et al., 1990 8/9 Decreased by 37%
Baronti et al., 1991 16/19 Decreased by 31.7%
Leu-enkephalin
(LEU-ENK)
Liu, 1989 22/19 Increased by 122% in untreated PD patients without further
modification by levodopa therapy
Dynorphin A(1-8) Baronti et al., 1991 16/19 Normal
Somatostatin Jolkkonen et al., 1986 35/19 Decreased by 22% (p < 0.01), especially in demented patients
Strittmatter and Cramer,
1992
38/12 Decreased by 27.5% (p < 0.01)
Strittmatter et al., 1996 35/11 Decreased p < 0.05, similar in untreated vs. treatment with
levodopa
Cramer et al., 1989 15/9 Decreased by 39%
Dupont et al., 1982 39/29 Decreased by 40%
Christensen et al., 1984 48/32 Decreased by 40%
Cramer et al., 1985 50/6 Decreased by 34%(controls were patients with essential tremor)
Masson et al., 1990 35/11 Decreased (p < 0.02), especially in untreated patients and in those
with more severe disease
Jost et al., 1990 68/6 Decreased by 28%
Hartikainen et al., 1992 35/34 Normal
Volicer et al., 1986 10/9 Normal
Beal et al., 1986 6/84 Normal
Poewe et al., 1990 22/11 Normal in PD patients with dementia (n = 11) and without dementia
(n = 11)
Espino et al., 1995 23/26 Increased by 47%, especially in demented patients
Neuropeptide Y (NPY) Martignoni et al., 1992 10/20 Decreased by 31%
Yaksh et al., 1990 8/9 Normal
Beta-endorphin Nappi et al., 1985 24/15 Decreased (p < 0.005) both in 14 untreated and 10 treated PD
patients
Jolkkonen et al., 1987 36/35 Normal
Arginine-vasopressine
(AVP)
Sundquist et al., 1983 11/21 Decreased by 68%
Olsson et al., 1987 12/32 OND Decreased by 71%
Vasoactive intestinal
peptide (VIP)
Sharpless et al., 1984 19/12 Normal
Delta sleep-inducing
peptide (DSIP)
Ernst et al., 1987 9/20 Decreased by 28.7% (Ferrero et al., 1988)
Alpha-melanocyte-
stimulating
hormone-like
Rainero et al., 1988 9/12 Increased by 2-fold
(Continued)
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Table 2 | Continued
Neuropeptide References PD patients/
Controls
Cerebrospinal fluid levels
Diazepam-binding
inhibitor
Ferrero et al., 1988 25/82 Increased by 42.5% (80% in depressed PD patients and normal in
non-depressed PD patients
Ferrarese et al., 1990 28/10 Decreased by 50% in PDD (n = 14), normal in PDND (n = 14)
Neurokinin A Galard et al., 1992 12/11 Decreased by 24%
Corticotropin-releasing
hormone (CRH)
Suemaru et al., 1995 10/5 Normal
ACTH Nappi et al., 1985 24/15 Normal
Beta-lipotropine Nappi et al., 1985 24/15 Normal
Angiotensin converting
enzyme (ECA)
Konings et al., 1994 88 PDND/18
PDD/20
Increased in PDND patients under levodopa therapy (p < 0.05).
Normal in untreated PDND and in PDD
Zubenko et al., 1985 10 PDD/30 Decreased by 27% in demented PD patients
Zubenko et al., 1986 15/10 Decreased by 24%
Chromogranin A and B
and secretogranin II
Eder et al., 1998 8/29 Normal
OND, other neurological diseases; PDD, Parkinson’s disease demented; PDND, Parkinson’s disease non-demented.
1995; Oeckl et al., 2012), while another found a non-significant
trend toward higher CSF cGMP levels in PD patients when
compared with controls and higher levels in levodopa-treated
PD patients compared with those without levodopa treatment
(Navarro et al., 1998).
BIOPTERIN DERIVATIVES AND OTHER COFACTORS
Biopterins act as cofactors for aromatic amino acid hydroxylases,
which produce a number of neurotransmitters including DA, NE,
epinepherine, and 5-HT and are also required for the produc-
tion of NO. CSF levels of neopterin and biopterin have been
found decreased in PD patients by several groups, especially in
those with early-onset PD (Fujishiro et al., 1990; Furukawa et al.,
1992), and in carriers of the PARK8 mutation (Koshiba et al.,
2011), which was negatively correlated with duration of illness
in those patients with akinetic-rigid PD (Furukawa et al., 1991).
In contrast, another group found increased CSF neopterin in PD
(Widner et al., 2002).
CSF concentration of hydroxylase cofactor, predominantly
composed of tetrahydrobiopterin (BH4), has also been found
decreased (Williams et al., 1980a,b).
Thiamine is an essential cofactor for several important
enzymes involved in brain oxidative metabolism. Our group
found normal CSF levels of thiamine-diphosphate, thiamine-
monophosphate, free thiamine, and total thiamine in PD patients
(Jiménez-Jiménez et al., 1999).
ENDOGENOUS NEUROTOXINS
One of the classical etiological hypotheses of PD is related with the
presence of endogenous substanceswhich share structural similar-
ities with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
a neurotoxin that induces a parkinsonism resembling PD.
Moser et al. (Moser and Kömpf, 1992; Moser et al., 1995)
identified two tetrahydroisoquinolin (TIQ) derivatives in the CSF
of PD patients, but not in healthy controls, 2-methyl and 1-
methyl-6,7-dihydroxy1,2,3,4-TIQ (2-MDTIQ and 1-MDTIQ or
salsolinol). This group described a relation between high sal-
solinol levels and the presence of visual hallucinations (Moser
et al., 1996), and reported an increased HVA/3OMD ratio in PD
patients in which 2-MDTIQ was detected when compared with
those PD in which it was not detectable.
CSF salsolinol levels have been reported to be increased in
PD patients compared with controls by other groups (Maruyama
et al., 1996; Antkiewicz-Michaluk et al., 1997; Krygowska-Wajs
et al., 1997; Naoi and Maruyama, 1999), especially in demented
PD patients (Antkiewicz-Michaluk et al., 1997), and in those
patients with more severe parkinsonism (Krygowska-Wajs et al.,
1997), although other authors have described a trend toward
decrease in CSF salsolinol levels with the progression of the dis-
ease (Maruyama et al., 1999). In contrast, another group reported
similar CSF salsolinol (Müller et al., 1999a,b), but higher lev-
els of harman and norharman β-carbolines (structural analogs
of MPTP as well) in PD patients than in controls (Kuhn et al.,
1996b). CSF levels of 1-benzyl-1,2,3,4-TIQ have also been found
by another group to be increased (Kotake et al., 1995).
Matsubara et al. (1995) measured β-carbolinium cations
(BC+s) in the lumbar CSF of 22 PD patients and 11 age-matched
controls, and found the 2,9-dimethylnorharmanium cation
(2,9-Me2NH+) in 12 PD patients but not in controls. This group
described decreased activity of nicotinamide N-methyltranserase
(NNMT), an enzyme that catalyzes the N-methylation of nicoti-
namide and other pyridines in the CSF of younger PD patients
compared with younger controls, and a trend toward decrease
with aging in PD patients (Aoyama et al., 2001).
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The results of studies on neurotoxins related with the risk for
PD are based on small series and are not conclusive.
OXIDATIVE STRESS MARKERS
Because there is much evidence on the contribution of oxida-
tive stress in the pathogenesis of PD (Figure 1) (Alonso-Navarro
et al., 2008), the measurement of oxidative stress markers and
substances related with oxidative and defense against oxida-
tive phenomena in the CSF of PD patients is useful. Data
regarding lipid peroxidation markers are controversial, while
DNA oxidation markers have been found to be increased
(Table 3).
Transition metals such as iron, copper, and manganese, act
as prooxidant agents, although copper is also essential for the
FIGURE 1 | Pathogenical mechanisms proposed for Parkinson’s disease (modified from Alonso-Navarro et al., 2008).
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antioxidant function of the protein ceruloplasmin, and copper
and manganese are constituents of the cytosolic Cu+2/Zn+2 and
the mitochondrial Mn+2-superoxide-dismutases (SOD, protec-
tive against oxidative processes). Zinc has antioxidant activity
and is a constituent of Cu+2/Zn+2-SOD (Jiménez-Jiménez et al.,
1998). The results of studies with CSF levels of iron and copper are
controversial (Table 3), but a recent meta-analysis showed simi-
lar values in PD patients to controls (Mariani et al., 2013), thus
suggesting that these metals are not useful as markers of PD.
Together with its role in glutamate excitotoxity, NO could con-
tribute to oxidative stress mechanisms in the pathogenesis of PD
by interacting with ferritin to release iron, inducing mitochon-
drial complex I damage (Molina et al., 1998), and by inducing
nitrosylation of proteins (Fernández et al., 2013). However, stud-
ies on CSF levels of nitrates and nitrites have given controversial
results (Table 3).
Among other antioxidant enzymes and substances (Table 3),
one study involving an important number of early PD patients
showed the relationship between the presence of relatively higher
levels of urate and the slower rates of clinical decline (Ascherio
et al., 2009), despite the fact that CSF urate levels were found to
be similar in PD patients and controls in the same study.
INFLAMMATORY AND IMMUNOLOGICAL MARKERS
CSF interleukin (IL) 1-β levels were found to be normal in
one study (Pirttila et al., 1994) and increased in three (Blum-
Degen et al., 1995; Mogi et al., 1996a; Mogi and Nagatsu, 1999),
CSF IL-2 normal (Blum-Degen et al., 1995) or increased (Mogi
et al., 1996a; Mogi and Nagatsu, 1999), IL-4 increased (Mogi
and Nagatsu, 1999), and CSF IL-10, IL-12, and interferon-gamma
levels have been reported to be similar in PD patients and con-
trols (Rota et al., 2006). CSF IL-6 levels have been found to
be decreased in PD patients with major depression in compar-
ison with patients with major depression without PD in one
study (Pålhagen et al., 2010), while another 4 found higher
CSF IL-6 in PD patients than in healthy controls (Blum-Degen
et al., 1995; Mogi et al., 1996a; Müller et al., 1998; Mogi and
Nagatsu, 1999), and in one of them CSF IL-6 was correlated
with PD severity (Müller et al., 1998). CSF tumor necrosis α
(TNF-α) levels have been found to be increased (Mogi et al.,
1994; Mogi and Nagatsu, 1999), leukotriene 4 (Irkeç et al., 1989),
and α-1-antichymotrypsin normal (Pirttila et al., 1994), and β-
2-microglobuline decreased in PD (Mogi et al., 1989; Mogi and
Nagatsu, 1999). The CSF levels of the cytokine fractalkine have
been found to be normal in PD patients and increased in multiple
system atrophy (MSA), and Flt3 ligand normal in these two dis-
eases (Shi et al., 2011). The presence of certain syalilated isoforms
of Serpin A1 in the CSF has been related with the development of
dementia in PD patients (Jesse et al., 2012).
CSF levels of pros-methylimidazol acetic acid, an isomer of the
histamine metabolite tele-methylimidazol acetic acid, have been
found to be decreased in PD (Prell et al., 1991), and were highly
positively correlated with the severity of the disease (Prell and
Green, 1991).
CSF complement 3 (C3) and factor H (FH) levels were
reported to be normal in one study (Wang et al., 2011), while
another described a decrease in several isoforms of C3b,C4b, FH,
and factor B (Finehout et al., 2005), and another normal C4d
(Yamada et al., 1994). CSF levels of heat shock proteins Hsp65
and Hsp70 have been found to be increased (Fiszer et al., 1996),
and PD patients have shown higher HLA-DR expression in CSF
monocytes in comparison with controls (Fiszer et al., 1994a).
Oligoclonal IgG bands have not been detected in the CSF of
PD patients (Chu et al., 1983), but antibodies against DA neurons
have been detected in 78% of PD patients and in only 3% of con-
trols (Carvey et al., 1991), and the CSF of PD patients has shown
a higher proportion of gamma-delta-T+ cells than in controls
(Fiszer et al., 1994b).
The results of studies on inflammatory and immunological
markers in PD have a low number of patients and controls
enrolled, and are inconclusive.
GROWTH AND NEUROTROPHIC FACTORS
CSF Brain Derived Neurotrophic Factor (BDNF) levels have been
found to be similar in PD patients with major depression to
those in patients with major depression without PD in one study
(Pålhagen et al., 2010), while another described this value as
increased in PD patients compared with controls (Salehi and
Mashayekhi, 2009). CSF Transforming Growth Factor α (TGF-α)
has been found to be increased in juvenile parkinsonism (Mogi
and Nagatsu, 1999). TGF-β1 has been found to be increased
(Mogi et al., 1995, 1996a; Vawter et al., 1996; Mogi and Nagatsu,
1999) or normal (Rota et al., 2006), and TGF-β2 increased
(Vawter et al., 1996). CSF insulin-like growth factor-1 (IGF-1)
and IGF binding proteins (IGFBPs) expression is increased in PD
patients (Mashayekhi et al., 2010). Finally, a single study found a
non-significant trend toward increased CSF levels of neuroreg-
ulins (which belong to the Epidermal Growth Factor or EGF
family) in PD patients (Pankonin et al., 2009). The results of
studies on growth and neurotrophic factors in PD, involving a
low number of patients and controls, do not permit definitive
conclusions.
PROTEINS INVOLVED IN THE PATHOGENESIS OF
PARKINSON’S DISEASE
MICROTUBULAR ASSOCIATED PROTEIN Tau (MAPT)
Because MAPT gene is one of the main genes involved in the
risk for PD (Alonso-Navarro et al., 2014), the measurement of
CSF protein tau levels are hypothetically useful as a marker of
this disease. Tau protein is important for maintaining the sta-
bility of axonal microtubules involved in the mediation of fast
axonal transport of synaptic constituents. Hyperphosphorylation
of tau causes reduces binding affinity for microtubules, leading
to their malfunction. Following neuronal damage, tau is released
into extracellular space and may be increased in the CSF. Tau is
an important component of the neurofibrillary tangles (pairwise,
helical protein filaments which are found in the cytoskeleton or
neuronal cells in Alzheimer’s disease (AD) brains. CSF tau protein
levels are increased in AD patients, and so are a useful marker for
this disease. The high risk of PD patients of developing cognitive
impairment or dementia patients makes measurement of CSF tau
reasonable as a possible marker of this disease.
Many studies have shown similar CSF total tau and phospho-
rylated tau (phosphotau) in PD patients to controls (Blennow
et al., 1995; Molina et al., 1997c; Jansen Steur et al., 1998; Sjögren
et al., 2002; Mollenhauer et al., 2006; Parnetti et al., 2008, 2011,
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Table 3 | Alterations in the CSF levels of oxidative stress markers and substances related with oxidative stress in PD patients compared with
controls.
References PD/Controls Cerebrospinal fluid levels
Lipid
peroxidation
markers
Malonyl-dialdehyde
(MDA)
Ilic´ et al., 1998 31/16 Increased (p < 0.001)
Ilic et al., 1999 33/16 Increased (p < 0.001)
Shukla et al., 2006 21/20 Normal
(E)-4-hydroxynonenal
(HNE)
Selley, 1998 10/10 Increased 4-fold
Low density lipoprotein
(LDL) oxidation products
Buhmann et al., 2004 70/60 OND/31 HC Increased 3-fold with –SH
decreased 1.5-fold
Schiff bases, conjugated
dienes, oxidized proteins,
and aldehyde polymers
Boll et al., 2008 22/41 Increased 1,5 fold (Isobe et al.,
2010b)
DNA oxidation
markers
8’-hydroxy-
2’deoxyguanine
(8-OHdG)
Kikuchi et al., 2002 48/22 Increased (p < 0.0001)
Isobe et al., 2010b 20/20 Increased (p < 0.0001)
8-hydrosyguanosine
(8-OHG)
Kikuchi et al., 2002 48/22 Increased
Abe et al., 2003 24/15 Increased 3-fold (p < 0.001)
8-OHdG/8-OHG ratio Kikuchi et al., 2002 48/22 Increased 2-fold (p < 0.0005)
Transition metals
and related
proteins
Iron Campanella et al., 1973 13/5 Normal
Pall et al., 1987 24/34 Normal
Gazzaniga et al., 1992 11/22 Normal
Takahashi et al., 1994 20/25 Normal
Pan et al., 1997 NS/NS Normal
Jiménez-Jiménez et al.,
1998
37/37 Normal
Hozumi et al., 2011 20/15 Normal
Forte et al., 2004 26/13 Decreased (p < 0.05)
Alimonti et al., 2007 42/20 Decreased (p < 0.05)
Qureshi et al., 2006 36/21 Increased
Ferritin Campanella et al., 1973 13/5 Normal
Dexter et al., 1990 26/11 Normal
Pall et al., 1990 24/21 Normal
Kuiper et al., 1994a 72 PDND/15 PDD/20 HC Normal
Transferrin Loeffler et al., 1994 12/11 Normal
Copper Campanella et al., 1973 13/5 Normal
Gazzaniga et al., 1992 11/22 Normal
Takahashi et al., 1994 20/25 Normal
Pan et al., 1997 NS/NS Increased (p < 0.05)
Jiménez-Jiménez et al.,
1998
37/37 Normal
Forte et al., 2004 26/13 Normal
Alimonti et al., 2007 42/20 Normal
Qureshi et al., 2006 36/21 Normal
Boll et al., 2008 22/41 Increased 2-fold
Pall et al., 1987 24/34 Increased (p < 0.001)
Hozumi et al., 2011 20/15 Increased 2-fold (p < 0.01)
Boll et al., 1999 49/26 (35 PD untreated) Increased 1,5 fold
(Continued)
Frontiers in Cellular Neuroscience www.frontiersin.org November 2014 | Volume 8 | Article 369 | 10
Jiménez-Jiménez et al. Cerebrospinal fluid in Parkinson’s disease
Table 3 | Continued
References PD/Controls Cerebrospinal fluid levels
Ceruloplasmin Campanella et al., 1973 13/5 Normal
Loeffler et al., 1994 12/11 Normal
Ferroxidase Boll et al., 2008 22/41 Decreased activity by 20%
Boll et al., 1999 49/26 (35 PD untreated) Decreased activity by 1.5-fold
Manganese Gazzaniga et al., 1992 11/22 Normal
Pan et al., 1997 NS/NS Normal
Jiménez-Jiménez et al.,
1998
Forte et al., 2004
37/37
26/13
Normal
Normal
Alimonti et al., 2007 42/20 Normal
Hozumi et al., 2011 20/15 Increased 1.5-fold (p < 0.05)
Zinc Takahashi et al., 1994 20/25 Normal
Pan et al., 1997 NS/NS Normal
Forte et al., 2004 26/13 Normal
Jiménez-Jiménez et al.,
1998
37/37 Decreased (p < 0.05)
Qureshi et al., 2006 36/21 Decreased
Hozumi et al., 2011 20/15 Increased 3-fold (p < 0.01)
Other metals Selenium Takahashi et al., 1994 20/25 Normal
Qureshi et al., 2006 36/21 Increased
Aguilar et al., 1998 28/43 Increased only in untreated PD
patients (p < 0.01)
Chromium Aguilar et al., 1998 28/43 Normal
Alimonti et al., 2007 42/20 Decreased by 50%
Magnesium Hozumi et al., 2011 20/15 Normal
Forte et al., 2004 26/13 Normal
Alimonti et al., 2007 42/20 Normal
Calcium Pan et al., 1997 NS/NS Normal
Forte et al., 2004 26/13 Normal
Alimonti et al., 2007 42/20 Normal
Aluminum Forte et al., 2004 26/13 Decreased (p < 0.05)
Alimonti et al., 2007 42/20 Normal
Silicon Forte et al., 2004 26/13 Normal
Alimonti et al., 2007 42/20 Decreased (p < 0.05)
Cobalt Alimonti et al., 2007 42/20 Decreased (p < 0.05)
Tin Alimonti et al., 2007 42/20 Decreased (p < 0.05)
Lead Alimonti et al., 2007 42/20 Decreased by 50%
Various Alimonti et al., 2007 42/20 Normal levels of barium, bismuth,
cadmium, mercury, molibdenum,
nickel, antimony, strontium, thallium,
vanadium, wolfram, and zirconium
(Continued)
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Table 3 | Continued
References PD/Controls Cerebrospinal fluid levels
Nitric oxide
metabo-
lites/nitroxidative
stress
Nitrates Ikeda et al., 1995 11/17 Normal
Molina et al., 1996 31/38 Normal
Kuiper et al., 1994b 103/20 Decreased
Boll et al., 2008 22/41 Increased 2-fold
Nitrites Ikeda et al., 1995 11/17 Normal
Ilic et al., 1999 33/? Normal
Kuiper et al., 1994b 103/20 Normal
Boll et al., 2008 22/41 Increased 2-fold
Qureshi et al., 1995 16/14 Increased 2-fold both in untreated
(n = 6) and in levodopa-treated (n = 10)
PD patients. Controls were young
Nitrotyrosine-containing
proteins
Fernández et al., 2013 54/40 Increased (p < 0.01)
Aoyama et al., 2000 10/6 Increased 1.8-fold
Antioxidant
enzymes or
substances
Total
superoxide-dismutase
(SOD)
Marttila et al., 1988 26/26 OND Normal
De Deyn et al., 1998 12/58 Normal
Cu/Zn-SOD (SOD-1) Ilic´ et al., 1998 31/16 Increased (p < 0.05)
Ilic et al., 1999 33/16 Increased (p < 0.05)
Boll et al., 2008 22/41 Decreased (p = 0.021)
Mn-SOD (SOD-2) Aoyama et al., 2000 10/6 Normal
Catalase Marttila et al., 1988 26/26 OND Normal
Glutathione peroxidase
(GPx)
Marttila et al., 1988 26/26 OND Normal
Glutathione reductase (GR) Ilic´ et al., 1998 31/? Increased
Ilic et al., 1999 33/? Increased
Reduced glutathione (GSH) Marttila et al., 1988 26/26 OND Normal
Tohgi et al., 1995b 22/15 Increased (p < 0.02) in L-dopa treated
patients (n = 8)
Konings et al., 1999 71 PD/13 PDND/21
HC
Normal
Oxidized glutathione
(GSSG)
LeWitt et al., 2013 48/57 Decreased (p < 0.01)
Tohgi et al., 1995b 22/15 Decreased (p < 0.001) in untreated
patients (n = 14)
Alpha-tocopherol (vitamin
E)
Buhmann et al., 2004 70/60 OND/31 HC Decreased by 44–48%
Tohgi et al., 1995b 22/15 Normal
Molina et al., 1997b 34/47 Normal
Alpha-tocopherol-quinone Tohgi et al., 1995b 22/15 Decreased (p < 0.001) in untreated
patients (n = 15)
Urate Tohgi et al., 1993e 11/14 Normal
Constantinescu et al.,
2013
6/18 Normal
Ascherio et al., 2009 713/0 Relation of higher CSF levels of urate
with slower rates of clinical decline
(Continued)
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Table 3 | Continued
References PD/Controls Cerebrospinal fluid levels
Xantine (uric acid
precursor)
LeWitt et al., 2011 217/26 Normal
Ascorbate Buhmann et al., 2004 70/60 OND/31 HC Normal
Carnitine Jiménez-Jiménez et al.,
1997
29/29 Normal
Oxidized coenzyme
Q10/total Q10 ratio
Isobe et al., 2010b 20/20 Increased 18% (p < 0.05)
Isobe et al., 2007 20/20 Increased 18% (p < 0.05)
Osteopontine Maetzler et al., 2007 30/30 Increased 2-fold (p < 0.002)
OND, other neurological controls; HC, healthy controls; PDND, Parkinson’s disease non-demented.
2014a,b; Ohrfelt et al., 2009; Compta et al., 2009b; Alves et al.,
2010; Montine et al., 2010; Aerts et al., 2011; van Dijk et al.,
2013a; Herbert et al., 2014). Several of these studies have shown
increased CSF tau in demented PD patients (Mollenhauer et al.,
2006; Compta et al., 2009b). The 33 KDa/55 KDa tau isoforms
ratio have also been found to be normal in PD (Borroni et al.,
2008, 2009), but decreased in progressive supranuclear palsy
(PSP), and normal in patients with diffuse Lewy body disease
(DLBD), demented PD patients (PDD), AD, and frontotemporal
dementia (FTD) (Borroni et al., 2008, 2009).
Some authors have found decreased CSF total tau and phos-
photau levels when compared with controls (Mollenhauer et al.,
2011; Shi et al., 2011; Kang et al., 2013) and similar levels in PD
to PSP, DLBD, and MSA (Mollenhauer et al., 2011), while oth-
ers found higher CSF tau in DLBD compared with PDD patients
(Andersson et al., 2011), and still others higher CSF total tau in
MSA than in PD patients (Herbert et al., 2014). Hall et al. (2012)
reported decreased CSF total tau and normal phosphotau both in
PD and PDD, while total tau was increased in CBD and normal
in PSP, DLBD, and MSA, and phosphotau was decreased in PSP
and MSA in comparison with controls.
Prˇikrylová Vranová et al. (2010) found increased CSF tau levels
in PD patients with less than 2 years of evolution, and increased
CSF tau levels which were higher in patients with PDD than in
PD, and in PD than in controls, and similar CSF tau in DLDB
than in controls (Vranová et al., 2014). This group and others
found increased CSF total tau levels in patients with non-tremor
variants of PD as compared to tremor-dominant PD and controls
(Jellinger, 2012; Prˇikrylová Vranová et al., 2012). Compta et al.
(2011) described increased CSF tau levels in PD patients carrying
the allele rs242557A. Siderowf et al. (2010) showed a lack of asso-
ciation between baseline CSF tau levels and cognitive decline in
PD patients. Patients with corticobasal degeneration (CBD) and
PSP have shown higher CSF total and phospotau levels (Aerts
et al., 2011), and patients with DLBD showed similar CSF tau
levels to PD patients in one study (Ohrfelt et al., 2009), while
other authors found higher CSF tau levels in AD than in DLBD,
in DLDB higher than in PDD, and in PDD higher than in PD
(Parnetti et al., 2008).
Baseline CSF levels of total and phosphotau in the DATATOP
study, involving 403 early PD patients, were negatively correlated
with disease progression assessed with the Unified PD Rating
Scale (UPDRS) (Zhang et al., 2013).
Beyer et al. (2013) reported a lack of correlation between CSF
levels of total and phosphotau, and ventricular size in 73 non-
demented PD patients and 18 PD patients with mild cognitive
impairment.
The results of the studies reported on CSF tau levels in
PD are summarized in Table 4. Although these results are not
conclusive, CSF tau levels could be related to the progres-
sion of the disease (Zhang et al., 2013), and to the preser-
vation of cognitive function in PD patients (Stewart et al.,
2014).
ALPHA-SYNUCLEIN
Alpha-synuclein (α-synuclein) is a 140 amino acid-long presy-
naptic protein, which is the major component of the Lewy bodies
(the neuropatologic hallmark of PD), and has been implicated
in the pathogenesis of PD and in synucleinopathies such as
MSA and DLBD. Mutations of the α-synuclein (SNCA) gene are
related with early-onset monogenic familial PD and are associ-
ated with increased risk for sporadic PD (Alonso-Navarro et al.,
2014). Although early studies failed to detect the native form
of α-synuclein in the CSF of PD and control patients (Jakowec
et al., 1998), later studies have detected monomeric SNC in the
CSF, with similar levels in PD patients and controls (Borghi
et al., 2000). Several studies have found similar CSF total α-
synuclein levels in PD patients and in controls (Woulfe et al.,
2002; Ohrfelt et al., 2009; Park et al., 2011; Parnetti et al., 2011;
Tateno et al., 2012) and others decreased CSF α-synuclein in
PD (Tokuda et al., 2006; Hong et al., 2010; Mollenhauer et al.,
2011, 2013; Hall et al., 2012; Wang et al., 2012; Kang et al.,
2013; Wennström et al., 2013; Parnetti et al., 2014a,b; Mondello
et al., 2014; van Dijk et al., 2014), DLBD (Parnetti et al., 2011;
Wennström et al., 2013), MSA (Wang et al., 2012; Mondello
et al., 2014), and PSP (Wang et al., 2012). Four studies have
reported increased CSF oligomeric α-synuclein levels in PD com-
pared with controls (Tokuda et al., 2010; Park et al., 2011; Parnetti
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Table 4 | Results of studies on CSF tau and phosphotau levels in PD, other parkinsonian syndromes and controls.
References Cases/Controls Main findings
Blennow et al., 1995 44 AD, 31 controls, 17VAD, 11 FTD, 15 PDND,
major depression
CSF total tau and phosphorylated tau (phosphotau)
higher in AD than in controls, VAD, FTD, PDND, and
major depression (PDND similar than controls)
Molina et al., 1997c 26 PDND, 25 controls CSF total tau similar in PD and controls
Jansen Steur et al., 1998 115 PD (48 with MMSE lower than 25) 15 controls CSF total and phosphotau similar in PD (not related
with MMSE scores) and controls
Sjögren et al., 2002 19 AD, 14 FTD, 11 ALS, 15 PD, 17 controls CSF total tau and phosphotau increased in AD
compared with FTD (p < 0.001), ALS (p < 0.001), PD
(p < 0.001), and controls (p < 0.001)
Mollenhauer et al., 2006 73 PDD, 23 PDND, 41 controls (non-demented
neurological patients)
CSF total tau significantly higher in PDD than in
PDND and controls. This observation was most
marked (p < 0.05) in a subgroup of patients with PDD
carrying the apolipoprotein genotype
epsilon3/epsilon3
Parnetti et al., 2008 19 DLBD, 18 PDD, 23 AD, 20 PDND, 20 controls CSF total tau of DLBD patients significantly lower
than in AD patients, but twofold to threefold higher
than in PDD, PDND, or control subjects
CSF total tau levels similar in PDD and PDND
Phosphotau increased in the AD group only
Borroni et al., 2008 21 PSP, 20 CBD, 44 FTD, 29 AD, 10 PDND, 15
DLBD, 27 controls
CSF tau 33/55 kDa ratio significantly reduced in PSP
when compared to controls and to patients with
other neurodegenerative conditions
CSF tau 33/55 kDa ratio decrease correlated
significantly with brainstem atrophy
Borroni et al., 2009 78 patients with neurodegenerative disorders and
26 controls
CSF tau 33/55 kDa ratio significantly decreased in
patients with PSP (0.46 ± 0.16) when compared to
healthy controls (p = 0.002), AD (P < 0.001), FTD,
CBD, PD, and DLBD (values in PD similar to those of
controls)
Ohrfelt et al., 2009 66 AD, 15 PD, 15 DLBD, 55 controls CSF total tau and phosphotau increased significantly
in AD, similar levels in PD, DLBD, and controls
Compta et al., 2009b 20 PDND, 20 PDD, 30 controls patients CSF total tau and phosphotau higher in PDD than in
PDND and controls (P < 0.05). High CSF total tau and
phospho-tau were associated with impaired memory
and naming
Alves et al., 2010 109 PDND, 36 controls, 20 mild AD CSF total tau and phosphotau similar in PD and
controls
CSF tau did not correlate with cognitive measures
Montine et al., 2010 150 controls (115 >50 years; 24 amnestic Mild
Cognitive Impairment (aMCI), 49 AD, 49 PD, 11
PDD 62 PD-CIND (cognitive imparment
non-demented)
CSF total tau and phospho181-tau significantly
increased in AD and aMCI in comparison with the
other groups
Total tau similar in PDD, PDD and PD-CIND and
controls
Phospho181-tau slightly decreased when compared
with controls >50 years
(Continued)
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Table 4 | Continued
References Cases/Controls Main findings
Prˇikrylová Vranová et al., 2010 32 PD, 30 controls CSF total tau and total tau/beta-amyloid (1-42) ratio
higher in PD than in controls (p = 0.045 and 0.033,
respectively)
Siderowf et al., 2010 45 PD, longitudinal follow-up at least 1 year No association between CSF total tau and
phospo181-tau and cognitive decline
Aerts et al., 2011 21 PSP, 12 CBD, 28 PD, 49 controls CSF total tau CBD > PSP > PD = controls
CSF phospotau CBD > PSP = PD = controls
Parnetti et al., 2011 38 PD, 32 DLBD, 48 AD, 31 FTD, 32 controls with
other neurological diseases (n = 32)
CSF total tau and phosphotau AD > FTD > DLBD =
PD = controls
Shi et al., 2011 137 controls, 126 PD, 50 AD and 32 MSA CSF total tau and phosphotau AD > controls > PD =
MSA
Mollenhauer et al., 2011 Cross-sectional cohort: 51 PD, 29 MSA, 55 DLBD,
62 AD, and 72 neurological controls
CSF total tau AD > DLBD > PD = controls = MSA
Mollenhauer et al., 2011 Validation cohort: 275 PD, 15 MSA, 55 66 DLBD, 8
PSP,22 normal pressure hydrocephalus (NPH) and
23 neurological controls
CSF total tau MSA < DLBD = PD < DLBD < controls
Andersson et al., 2011 47 DLBD, 17 PDD (n = 17) CSF total-tau higher in DLBD than in PDD
CSF phosphotau similar in DLBD and PDD
Compta et al., 2011 38 PD patients (19 PDD, 19 PDND). All cases were
genotyped for a series of tau gene polymorphisms
rs1880753, rs1880756, rs1800547, rs1467967,
rs242557, rs2471738, and rs7521
The A-allele rs242557 polymorphism was the only tau
gene variant significantly associated with higher CSF
tau and phospho-tau levels, under both dominant and
dose-response model. This association depended on
the presence of dementia, and was only observed in
individuals with low (<500 pg/mL) CSF Aβ levels
Hall et al., 2012 90 PDND, 33 PDD, 70 DLBD, 48 AD, 45 PSP, 48
MSA, 12 CBD, 107 controls
CSF total tau AD > MSA = CBD > PSP = Controls =
DLBD > PDND = PDD
CSF phosphotau increased in AD, AD > PDD =
DLBD = controls = CBD > PDND > PSP = MSA
Prˇikrylová Vranová et al., 2012 48 PD (17 early-onset PD, 15 tremor dominant, 16
non-tremor-dominant), 19 neurological controls, 18
AD
CSF tau and index tau/amiloid beta42 increased in
non-tremor-dominant PD compared with controls, and
other PD groups, and siminar to those of AD
Jellinger, 2012 12 PD (6 tremor-dominant PD and 6
non-tremor-dominant PD), 27 AD, 17 controls
CSF total tau higher in AD compared with the other
groups, and higher in tremor-dominant PD compared
with non-tremor dominant PD and controls
van Dijk et al., 2013a 52 PD, 50 controls CSF total tau and phosphotau similar in PD and
controls
Kang et al., 2013 63 PD, 39 controls CSF total tau and phosphotau181 significantly lower
in PD than in controls
Zhang et al., 2013 403 early stage PD patients enrolled in the
DATATOP study
Baseline CSF phosphotau/total tau and
phosphotau/amyloid beta significantly and negatively
correlated with the rates of the Unified Parkinson
Disease Rating Scale change
Beyer et al., 2013 73 PDND, 18 PD with mild cognitive impairment No associations between CSF total tau and
phosphotau and hippocampal atrophy
(Continued)
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Table 4 | Continued
References Cases/Controls Main findings
Herbert et al., 2014 43 PD, 23 MSA, 30 controls CSF total tau significantly lower in PD than in MSA,
but similar to those of controls
CSF phosphotau similar in PD, MSA and controls
Parnetti et al., 2014a 71 PD (8 of 44 carriers of a mutation in the
beta-glucocerebrosidase gene (GBA1) 45 controls
with other neurological disases
CSF total tau and phosphotau similar in PD and
controls
Parnetti et al., 2014b 44 PD and 25 controls with other neurological
diseases
CSF total tau and phosphotau similar in PD and
controls, and unrelated with prognosis and cognitive
impairment
Vranová et al., 2014 27 PDND, 14 PDD, 14 DLBD, 17 AD 24 controls CSF total tau AD > PDD > PDND > DLBD = controls
AD, Alzheimer’s disease; PD, Parkinson’s disease; VAD, vascular dementia; FTD, frontotemporal dementia; PDND, PD non-demented; PD, PD demented; MMSE,
MiniMental State Examination; DLBD, diffuse Lewy body disease; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; MSA, multiple system
atrophy; aMCI, Amnestic Mild Cognitive Impairment; PD-CIND, PD with cognitive imparment non-demented; NPH, normal pressure hydrocephalus.
et al., 2014a,b), and one of them showed increased CSF α-
Syn in PD patients compared with patients with PSP and AD
(Tokuda et al., 2010). Wang et al. (2012) found increased CSF
levels of the phosphorylated α-synuclein phospho-Ser129 (PS-
129) in PD patients when compared with controls, but lower
levels in MSA and PSP of this protein than in PD patients and
controls.
Aerts et al. (2012) found similar CSF α-synuclein levels in
PD patients to DLBD, PSP, and MSA. Hall et al. (2012) found
higher CSF α-synuclein in PSP than in PD, PDD, DLBD, and
MSA. Tateno et al. (2012) reported similar CSF α-synuclein
levels in PD, MSA, DLBD, and controls but higher CSF α-
synuclein levels in AD patients, while Ohrfelt et al. (2009) found
higher CSF α-Syn levels in AD than in DLDB and PD, and in
DLBD than in PD patients. Foulds et al. (2012) found similar
post-mortem CSF total α-synuclein levels in PD, MSA, DLBD,
and PSP, but increased CSF levels of phosforylated oligomers
in MSA.
van Dijk et al. (2014) reported a lack of relation between CSF
α-synuclein levels and striatal dopaminergic deficit measured by
dopamine transporter binding and single photon emission com-
puted tomography. In addition, a recent study by Shi et al. (2012)
described a lack of relation between the loss of striatal dopamin-
ergic function, assessed by positron emission tomography (PET),
and CSF α-synuclein levels, in asymptomatic carriers of muta-
tions in the LRRK2 gene. CSF neurosin (a protease that degrades
α-synuclein) levels have been found to be decreased (Wennström
et al., 2013).
Lower baseline CSF α-synuclein levels in the DATATOP study
predicted a better preservation of cognitive function in early PD
patients with up to 8 years of follow-up (Stewart et al., 2014).
The results of the studies reported on CSF α-synuclein levels
in PD are summarized in Table 5. The majority of recent studies
have shown decreased CSF α-synuclein levels both in PD and in
other synucleopathies. Therefore, this should be a useful marker
to distinguish this disease from controls, but not to distinguish
among synucleopathies.
AMYLOID-BETA
Amyloid beta (Aβ) are a group of different lengths peptides result-
ing from the enzymatic cleavage of the amyloid precursor protein
(APP). The most common is the 42 amino-acid long Aβ42.
These peptides have a differential trend toward aggregation (spe-
cially Aβ1-42) to form amyloid plaques, one of the pathological
hallmarks of AD and DLBD. The increased risk for developing
cognitive impairment and dementia of PD patients in compari-
son with the general population makes it reasonable to link AD
markers such as Aβ42 to PDD. Several studies have shown simi-
lar (Holmberg et al., 2003; Mollenhauer et al., 2006; Ohrfelt et al.,
2009; Prˇikrylová Vranová et al., 2010; Aerts et al., 2011; Parnetti
et al., 2011; van Dijk et al., 2013a) or decreased (Sjögren et al.,
2002; Compta et al., 2009b; Mollenhauer et al., 2011; Shi et al.,
2011; Kang et al., 2013; Nutu et al., 2013a; Vranová et al., 2014)
CSF Aβ1-42 (Aβ1-42) in PD patients, with the exception of one
study which reports increased levels (Parnetti et al., 2014b). Other
found decreased CSF Aβ-1-42 (Mollenhauer et al., 2006; Compta
et al., 2009b; Alves et al., 2010; Montine et al., 2010; Siderowf
et al., 2010) and Aβ1-40 (Alves et al., 2010) and Aβ1-38 (Alves
et al., 2010) only in PDD patients or in PD patients with memory
impairment.
Baseline CSF Aβ levels in the DATATOP study, were nega-
tively correlated with disease progression assessed with UPDRS
(Zhang et al., 2013). Baseline CSF levels of Aβ1-42 in two
studies (Siderowf et al., 2010; Parnetti et al., 2014b); and the
combination of lower baseline CSF Aβ, worse verbal learn-
ing, semantic fluency and visuoperceptual scores, and thinner
superior-frontal/anterior cingulated in precentral regions by 3T-
brain-Magnetic Resonance Imaging in another (Compta et al.,
2013) have been associated with further cognitive decline in PD
patients.
CSF Aβ1-42 levels have been reported as decreased (Parnetti
et al., 2008; Andersson et al., 2011; Parnetti et al., 2011) or similar
(Ohrfelt et al., 2009; Nutu et al., 2013a) in DLBD than in PDD
and PD patients, decreased in MSA (Holmberg et al., 2003; Shi
et al., 2011), and decreased in DLBD in comparison with PD,
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Table 5 | Results of studies on CSF alpha-synuclein and phosphotau levels in PD, other parkinsonian syndromes and controls.
References Cases/Controls Main findings
Borghi et al., 2000 12 PD, 10 controls Identification of a 19 kDa band that corresponds to monomeric
α-synuclein (similar levels in PD and controls)
Woulfe et al., 2002 5 PD, 4 controls Similar anti-α-synuclein antibodies in PD and controls
Tokuda et al., 2006 33 PD, 38 controls (9 healthy and 29 with OND) CSF α-synuclein levels significantly lower in PD than in controls
(p < 0.0001)
Ohrfelt et al., 2009 66 AD, 15 PD, 15 DLBD, 55 controls CSF α-synuclein AD > Controls = DLBD = PD
Hong et al., 2010 117 PD, 132 controls, 50 AD CSF α-synuclein PD < Controls = AD (after correcting for hemoglobin
levels)
Tokuda et al., 2010 32 PD, 28 controls (12 healthy and 16 with OND) CSF α-synuclein oligomers and oligomers/total-α-synuclein ratio in CSF
higher in PD group (p < 0.0001)
Tokuda et al., 2010 25 PD, 18 PSP, 35 AD, 43 controls CSF α-synuclein PD > PSP = Controls > AD
Parnetti et al., 2011 38 PD, 32 DLBD, 48 AD, 31 FTD, 32 controls with
other neurological diseases (n = 32)
CSF α-synuclein Controls > PD > DLBD = AD = FTD
Mollenhauer et al., 2011 Cross-sectional cohort: 51 PD, 29 MSA, 55
DLBD, 62 AD, and 72 neurological controls
CSF α-synuclein PD < DLBD < MSA < controls < AD
Kang et al., 2013 Validation cohort: 275 PD, 15 MSA, 55 66 DLBD,
8 PSP, 22 NPH, and 23 neurological controls
CSF α-synuclein MSA < DLBD = PD < NPH = PSP < controls
Park et al., 2011 23 PD, 29 neurological controls CSF α-synuclein oligomer significantly higher in PD than in neurological
controls
Kang et al., 2013 63 PD, 39 controls Slightly, but significantly, lower CSF levels of α-synuclein in PD
compared with healthy controls
Lower levels of CSF α-synuclein associated with increased motor
severity
Hall et al., 2012 90 PDND, 33 PDD, 70 DLBD, 48 AD, 45 PSP, 48
MSA, 12 CBD, 107 controls
CSFα-synuclein AD > PSP = Controls > PDD = DLBD = MSA = CBD
= PDND
Tateno et al., 2012 9 AD, 6 DLBD, 11 PD, 11 MSA, 11 neurological
controls
CSFα-synuclein levels in AD higher than in controls (P < 0.05), and
significantly lower in PD (P < 0.001), DLBD (P < 0.01), and MSA
(P < 0.05) when compared with AD
Wang et al., 2012 Discovery series: 93 PD, 26 AD, 78 controls, 33
PSP, 16 MSA
CSF Phosphorylated α-synuclein (PS-129) PD > Controls > AD > MSA
= PSP
Replication series: 116 PD, 50 AD, 126 controls,
27 PSP, 25 MSA
CSFα-synuclein MSA < PD < PSP > AD = Controls
CSF PS-199/α-synuclein ratio MSA > PK > AD > PSP = Controls
Aerts et al., 2012 58 PD, 47 MSA, 3 DLBD, 22Vascular
Parkinsonsim, 10 PSP, 2 CBD, 57 controls
CSFα-synuclein did not differ significantly among the study groups
Foulds et al., 2012 13 PDND, 10 PD with cognitive impairment, 16
PDD, 17 DLBD, 12 PSP, 8 MSA, 20 controls
(ventricular CSF obtained post-mortem)
CSF total α-synuclein, oligomeric α-synuclein and phosphorylated
α-synuclein similar in PDND, PDCI, PDD, DLBD, PSP, MSA, and control
groups
CSF oligomeric phosphorylated α-synuclein significantly higher in MSA
(p < 0.001) when compared with the other study groups
Shi et al., 2012 8 symptomatic and 18 asymptomatic carriers of
the G2019 mutation in the LRRK2 gene
Lack of correlation between PET scan evidence of loss of striatal
dopaminergic and CSF α-synuclein levels
(Continued)
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Table 5 | Continued
References Cases/Controls Main findings
Mollenhauer et al.,
2013
78 PD (drug naive), 48 controls CSF α-synuclein lower in PD than in controls
Wennström et al., 2013 52 controls, 46 AD,38 PDND, 22 PDD, 33 DLBD AD > controls > DLBD > PD > PDD
Parnetti et al., 2014a 71 PD (8 of 44 carriers of a mutation in the
beta-glucocerebrosidase gene (GBA1) 45
controls with other neurological diseases
CSF α-synuclein lower and oligomeric/total α-synuclein ratio higher in
PD than in controls
Parnetti et al., 2014b 44 PD and 25 controls with other neurological
diseases
CSF total α-synuclein lower and oligomeric α-synuclein higher in PD
than in controls. No relation with prognosis and cognitive impairment
van Dijk et al., 2014 53 PD, 50 controls CSF α-synuclein levels reduced in patients with PD, but not correlated
with measures of disease severity, and striatal dopaminergic deficit
assessed with neuroimaging
Mondello et al., 2014 22 controls, 52 PD, 34 MSA, 32 PSP, 12 CBD CSF α-synuclein MSA < PD < PSP < CBD < Controls
Stewart et al., 2014 304 early PD patients enrolled in the DATATOP
study. Longitudinal follow-up
CSF α-synuclein showed a longitudinal decrease over follow-up period
CSF α-synuclein was not correlated with the rate of clinical progression
of the motor symptoms
Lower basal levels of CSF α-synuclein were associated with better
preservation of cognitive function
AD, Alzheimer’s disease; PD, Parkinson’s disease; FTD, frontotemporal dementia; PDND, PD non-demented; PD, PD demented; OND, Other neurological diseases;
DLBD, diffuse Lewy body disease; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; MSA, multiple system atrophy; NPH, normal pressure
hydrocephalus.
PDD (Hall et al., 2012; Vranová et al., 2014), PSP, MSA, and CBD
(Hall et al., 2012).
Alves et al. (2013) reported that patients with PD with the
postural instability-gait disorders (PIGD) phenotype had signif-
icantly reduced CSF Aβ42, Aβ38, Aβ42/40, and Aβ38/40 levels
compared with patients with the tremor-dominant phenotype
and controls.
Nutu et al. (2013b) described lower CSF levels of Aβ1-15/16 in
PD, PDD, PSP, and MSA compared to CBD, AD, and controls.
Beyer et al. (2013) reported a correlation between CSF lev-
els of Aβ38, Aβ40, and Aβ42, and ventricular size in 73 non-
demented PD patients and 18 PD patients with mild cognitive
impairment.
The results of the studies reported on CSF Aβ levels in PD
are summarized in Table 6. Many of these studies suggest the
potential usefulness of CSF Aβ1-42 levels to predict cognitive
impairment in PD patients.
NEUROFILAMENT PROTEINS
Abnormal accumulation in the cytoplasm of neurofilaments
(NF), members of the cytoskeleton proteins expressed by neu-
rons, have been detected in neurodegenerative diseases includ-
ing AD, MSA, DLBD, and PD. CSF levels of neurofilament
light (NFL) proteins have been found normal in PD patients
(Constantinescu et al., 2010; Hall et al., 2012), and increased
in patients with PSP (Holmberg et al., 1998; Constantinescu
et al., 2010; Hall et al., 2012), MSA (Holmberg et al.,
1998; Constantinescu et al., 2010; Hall et al., 2012), CBD
(Constantinescu et al., 2010; Hall et al., 2012), and PDD (Hall
et al., 2012).
CSF neuronal thread protein (NTP) levels have been found
increased when compared with controls and decreased when
compared with AD patients in one study (de la Monte et al.,
1992), and similar to those of controls in another (Yamada et al.,
1993). CSF annexine V has been found to be decreased in PD
(Vermes et al., 1999). Glial fibrilar acidic protein (GFAP) has
been found to be normal in the CSF of PD, MSA, PSP, and CBD
patients (Constantinescu et al., 2010). CSF levels of the glial acti-
vation marker YKL-40 have been found to be decreased in PD,
MS, PSP, and CBD (Olsson et al., 2013).
OTHER PROTEINS
Defects in the gene encoding DJ-1 protein cause an autoso-
mal recessive early-onset PD, PARK7 (Alonso-Navarro et al.,
2014). This protein is also a marker of oxidative stress. CSF
levels of DJ-1 protein have been found to be increased in PD
in 2 studies (Waragai et al., 2006; Herbert et al., 2014) and
decreased in another 2 (Shi et al., 2011; Hong et al., 2010). One
of these studies described decreased CSF DJ-1 in MSA as well
(Shi et al., 2011), and other increased DJ-1 in MSA compared
with PD and with controls (Herbert et al., 2014). Shi et al. (2012)
described a lack of relation between the loss of striatal dopamin-
ergic function and CSF DJ-1 levels in asymptomatic carriers of
mutations in the LRRK2 gene (PARK8). The results on DJ-1
are, therefore, inconsistent and should not be considered as a
marker of PD.
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Table 6 | Results of studies on CSF amiloyd beta (Aβ) levels in PD, other parkinsonian syndromes and controls.
References Cases/Controls Main findings
Sjögren et al., 2002 19 AD, 14 FTD, 11 ALS, 15 PD, 17 controls CSF Aβ42 markedly decreased in AD = ALS < FTD < PD < controls
Holmberg et al., 2003 36 MSA, 48 PD, 15 PSP, 32 controls CSF Aβ42 MSA < PSP = controls = PD
Mollenhauer et al., 2006 73 PDD, 23 PDND, 41 controls
(non-demented neurological patients)
CSF Aβ42 lower in the PDD patients compared to PDND patients
and controls. This observation was most marked (p < 0.05) in a
subgroup of patients with PDD carrying the apolipoprotein genotype
epsilon3/epsilon3
Parnetti et al., 2008 19 DLBD, 18 PDD, 23 AD, 20 PDND, 20
controls
DLBD showed the lowest mean CSF Aβ42 levels, with a negative
association to dementia duration. PDD patients had mean CSF Aβ42
similar to those seen in PD patients
Ohrfelt et al., 2009 66 AD patients, 15 PD patients, 15
patients with dementia with Lewy bodies
(DLBD) and 55 cognitively normal controls
CSF Aβ42 AD < DLBD < PD = Controls
Compta et al., 2009b 20 PDND, 20 PDD, 30 controls patients CSF Aβ42 ranged from high (controls) to intermediate (PDND) and
low (PDD) levels (P < 0.001). In all PD and PDD patients, in PDND,
CSF Aβ42 was related with phonetic fluency
Alves et al., 2010 109 PDND, 36 controls, 20 mild AD CSF Aβ42 (19%; p = 0.009), Aβ40 (15.5%; p = 0.008), and Aβ38
(23%; p = 0.004) significantly decreased in PD compared with
controls
CSF Aβ42 reductions in PD less marked than in AD (53%;
p = 0.002)
Associations between CSF levels of Aβ42 (β = 0.205; p = 0.019),
Aβ40 (β = 0.378; p < 0.001), and Aβ38 (β = 0.288; p = 0.001) and
memory impairment, but not executive-attentional or visuospatial
dysfunction
Montine et al., 2010 150 controls (115 >50 years; 24 amnestic
Mild Cognitive Impairment (aMCI), 49 AD,
49 PD, 11 PDD 62 PD-CIND (cognitive
imparment non-demented)
CSF Aβ42 levels reduced in AD (p < 0.001), PD-CIND (P < 0.05),
and PDD (P < 0.01), and similar to those of controls in PD
Prˇikrylová Vranová et al., 2010 32 PD, 30 controls CSF Aβ1-42 similar in PD and controls
Siderowf et al., 2010 45 PD, longitudinal follow-up at least 1 year Lower baseline CSF Aβ1-42 associated with more rapid cognitive
decline
Subjects with CSF Aβ1-42 levels =192 pg/mL declined an average of
5.85 (95% confidence interval 2.11–9.58, p = 0.002) points per year
more rapidly on the DRS-2 than subjects above that cutoff, after
adjustment for age, disease duration, and baseline cognitive status
Aerts et al., 2011 21 PSP, 12 CBD, 28 PD, 49 controls CSF Aβ1-42 similar in CBD, PSP, PD, and controls
Parnetti et al., 2011 38 PD, 32 DLBD, 48 AD, 31 FTD, 32
controls with other neurological diseases
CSF Aβ1-42 controls = PD > DLBD = AD = FTD
Shi et al., 2011 137 controls, 126 PD, 50 AD and 32 MSA CSF Aβ1-42 controls = PD = _MSA > AD
Mollenhauer et al., 2011 Validation cohort: 275 PD, 15 MSA, 55 66
DLBD, 8 PSP, 22 NPH, and 23 neurological
controls
CSF Aβ1-42 DLBD < MSA = NPH = PD < controls < PSP
Andersson et al., 2011 47 DLBD, 17 PDD Aβ42 lower in DLBD than in PDD
Kang et al., 2013 63 PD, 39 controls Slightly, but significantly, lower levels of Aβ1-42 in PD compared
with controls
(Continued)
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References Cases/Controls Main findings
Hall et al., 2012 90 PDND, 33 PDD, 70 DLBD, 48 AD, 45
PSP, 48 MSA, 12 CBD, 107 controls
CSF Aβ1-42 AD < DLBD = PDD = PSP = MSA = CBD = PDND =
Controls
Prˇikrylová Vranová et al., 2012 48 PD (17 early-onset PD, 15
tremor-dominant, 16
non-tremor-dominant), 19 neurological
controls, 18 AD
CSF Aβ42 lower in AD than in the other groups, and lower in
non-tremor-dominant PD compared with controls
Jellinger, 2012 12 PD (6 tremor-dominant PD and 6
non-tremor-dominant PD), 27 AD, 17
controls
CSF Aβ42 lower in tremor-dominant PD than in non-tremor-dominant
PD and AD, and lower in these three groups than in controls
van Dijk et al., 2013a 52 PD, 50 controls CSF Aβ42 similar in PD and controls
Zhang et al., 2013 403 early stage PD patients enrolled in the
DATATOP study
CSF baseline levels of Aβ42 weakly but negatively correlated with
baseline Unified Parkinson Disease Rating Scale total scores
Beyer et al., 2013 73 PDND, 18 PD with mild cognitive
impairment
Association between CSF Aβ38, Aβ40, and Aβ42 with the radial
distance of the occipital and frontal horns of the lateral ventricles in
PDND. Negative association between CSF Aβ38 and Aβ42 with
enlargement in occipital and frontal horns of the lateral ventricles in
the pooled sample, and with enlargemente of the occipital horns in
PD with mild cognitive impairment
Nutu et al., 2013a 43 PDND, 33 PDD, 51 DLBD, 48 AD, 107
controls
CSF Aβ1-40 AD < DLDB < PDD < PDND = controls
CSF Aβ1-42 PDD = DLBD = PDND < controls = AD
CSF Aβ1-40/Aβ1-42 ratio AD < DLDB < PDD = controls = PD
Compta et al., 2013 27 PDND, longitudinal following (11
developed dementia)
Lower CSF amyloid-β predicted development of dementia together
with worse verbal learning, semantic fluency and visuoperceptual
scores, and thinner superior-frontal/anterior cingulate and precentral
regions
Alves et al., 2013 99 PD de novo (39 with postural
instability/gait disorders –PIGD—and 60
tremor-dominant—TD), 46 controls
CSF Aβ42, Aβ38, Aβ42/40, and Aβ38/40 levels significantly reduced
in PIGD phenotype compared with TD phenotype and with controls
(TD similar to controls)
Nutu et al., 2013b 90 PDND, 32 PDD, 68 DLBD, 48 AD, 45
PSP, 46 MSA, 12 CBD, 107 controls
Significantly lower levels of Aβ1-15/16 were detected in PD, PDD,
PSP, and MSA compared to other neurodegenerative diseases and
controls
Parnetti et al., 2014b 44 PD and 25 controls with other
neurological diseases
CSF Aβ42 lower in PD than in controls. This value was related with
cognitive impairment
Vranová et al., 2014 27 PDND, 14 PDD, 14 DLBD, 17 AD 24
controls
CSF Aβ42 PDND > PDD > DLBD >AD > controls
AD, Alzheimer’s disease; PD, Parkinson’s disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; PDND, PD non-demented; PD, PD demented;
DLBD, diffuse Lewy body disease; PSP, progressive supranuclear palsy; CBD, corticobasal degeneration; MSA, multiple system atrophy; aMCI, Amnestic Mild
Cognitive Impairment; PD-CIND, PD with cognitive imparment non-demented; NPH, normal pressure hydrocephalus; PIGD, Postural instability and gait disorder; TD,
tremor-dominant.
Defects in the gene encoding ubiquitin carboxy-terminal
hydrolase 1 (UCH-L1) cause familial PD, PARK5. A recent study
found decreased CSF UCH-L1 levels in PD, MSA, and PSP
compared with controls (Mondello et al., 2014).
Among proteins related with apoptosis, Bcl-2 protein has not
been detected in the CSF of PD patients (Mogi et al., 1996b; Mogi
and Nagatsu, 1999). CSF levels of clusterin have been reported
to be increased (Prˇikrylová Vranová et al., 2010; Vranová et al.,
2014) or normal (van Dijk et al., 2013a), tissue transglutaminase
(Vermes et al., 2004) increased in PD, and cystatin C normal in
PD (Prˇikrylová Vranová et al., 2010; Yamamoto-Watanabe et al.,
2010) and decreased in MSA (Yamamoto-Watanabe et al., 2010).
Studies measuring CSF levels of lysosomal hydrolases
(involved in the α-Syn degradation) found decreased (Balducci
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et al., 2007), normal (van Dijk et al., 2013b), or increased
(Parnetti et al., 2014a) β-hexosaminidase, increased cathepsin E
(van Dijk et al., 2013b), decreased α-mannosidase (Balducci et al.,
2007), decreased (Balducci et al., 2007) or normal β-mannosidase
(Mollenhauer et al., 2011; van Dijk et al., 2013b), decreased
α-fucosidase (van Dijk et al., 2013b), β-glucocerebrosidase
decreased (Balducci et al., 2007; Parnetti et al., 2014a) or normal
(van Dijk et al., 2013b), β-galactosidase increased (van Dijk et al.,
2013b) or normal (Balducci et al., 2007; Parnetti et al., 2014a),
and cathepsin D normal (van Dijk et al., 2013b) in PD patients
compared with controls.
CSF Prion protein (PrP) (Meyne et al., 2009) and tetranectin
(involved in tissue remodeling) (Hong et al., 2010) levels have
been found to be decreased, and apolipoprotein A-1 normal
(Wang et al., 2010) in PD patients. CSF levels of transthyretin
(TTR, a clearance protein produced in the choroid plexus) have
been found to be increased in Lewy body diseases, including PD,
PDD, and DLBD in relation with controls (Maetzler et al., 2012).
CSF levels of the soluble proteoglycan NG2 (sNG2), involved in
proliferation, migration, and differentiation of perycites and NG2
cells in the brain, have been found to be similar in PD patients and
controls, and decreased in DLBD (Nielsen et al., 2014).
In PD patients there are reports of decreased CSF post-
proline cleaving enzyme (Hagihara and Nagatsu, 1987), increased
dipeptidyl-aminopeptidase II (Hagihara et al., 1987), normal
dipeptidyl-aminopeptidase IV (Hagihara et al., 1987), and
normal glutamic oxaloacetic transaminase (GOT) (Steen and
Thomas, 1962; Weiss et al., 1975; Qureshi et al., 1995) and
glutamic pyruvic transaminase (GPT) (Weiss et al., 1975)
levels.
OTHER COMPOUNDS
In patients with PD there have been reports of normal CSF lev-
els of the proteoglycan N-acetyl neuraminic acid (Lipman and
Papadopoulos, 1973), and CSF insulin levels (Jiménez-Jiménez
et al., 2000) have been found normal in PD patients.
The CSF levels of corticosterone (Pålhagen et al., 2010) and
neuroactive steroids such as allopregnanolone (THP) and 5 α-
dihydroprogesterone (DHP) (di Michele et al., 2003) have been
found to be decreased in PD. Björkhem et al. (2013) reported that
10% of the PD patients were found to have increased CSF levels
of 24S-hydroxycholesterol, and that there was a significant corre-
lation between this value and duration of the disease. Lee et al.
(2008) described a significant increase in the CSF levels of the
polyunsaturated fatty acid eicosapentanoic acid (EPA) in patients
with PD and MSA.
Paik et al. (2010) measured several polyamines in the CSF
of patients with PD, MSA and controls. These substances are
important for cell growth, and act as important modulators
of a variety of ion channels, including glutamate NMDA and
AMPA receptors. CSF total polyamine, N1acetyl-cadaverine, and
cadaverine levels were increased both in PD and MSA, but PD
patients showed higher CSF putrescine and lower CSF spermi-
dine levels than MSA and controls, and MSA patients showed
lower CSF N1acetylputrescine than PD and controls. CSF N8-
acetylspermidine levels were higher in PD patients than in
controls, and in MSA than in PD patients and controls.
CONCLUSIONS
(A) The majority of classical biochemical studies on neurotrans-
mitter and related substances have described decreased CSF
HVA, and normal NE,MHPG, ACh, AChE, glutamate, aspar-
tate, and glycine levels in patients with PD. Results on CSF
GABA and 5-HIAA levels are controversial. Many of these
classical studies included patients with different types of
Parkinsonism and had a limited number of patients and
controls.
(B) Studies on the possible value of endogenous neurotoxins,
oxidative stress markers, inflammatory and immunological
markers, and growth and neurotrophic factors as biological
markers of PD should be considered as inconclusive. The
most consistent finding related with these issues is the pos-
sible role of CSF urate on the progression of the disease
(Ascherio et al., 2009).
(C) Data regarding the role of CSF total tau and phosphotau as
biological markers for PD are inconsistent. The most inter-
esting findings are the possible relations of these markers
with the progression of the disease (Zhang et al., 2013), and
with the preservation of cognitive function in PD patients
(Stewart et al., 2014).
(D) CSF α-synuclein levels have been found to be decreased in
most, but not all, studies in PD patients compared with
controls. This marker should be useful for the differential
diagnosis between synucleopathies and other parkinsonian
syndromes, but its usefulness to differentiate among synu-
cleopathies (PD, PDD, DLBD, and MSA), remains to be
elucidated.
(E) CSF Aβ1-42 levels could be considered as a useful marker of
the presence of further cognitive decline in PD patients.
(F) CSF NFL protein levels should be useful for the differential
diagnosis of PSP, MSA, CBD, and PDD from PD, but not to
discriminate between PD and healthy controls.
FUTURE APPROACHES
While possible biomarkers for PD in classical studies have been
hypothesis-driven, attempts to develop effective procedures for
the differential diagnosis of PD in its early stages have led to the
performance of CSF multianalyte methods including systematic
measurements of patterns of variation in proteins (proteomics)
or small molecules (metabolomics). These methods have led to
the identification of possible unexpected biomarkers of diseases
involved in neurodegenerative processes. However, the results of
these types of studies, which are briefly described below, are not
clearly established and await replication.
Guo et al. (2009), in a proteomic analysis of the CSF of PD
patients and controls, found significantly higher CSF levels of
apolipoprotein E, autotoxin, and some SOD1 isoforms, and lower
levels of complement C4 when compared with controls, while
Pigment epithelium-derived factor (PEDF or serpin F1) was not
significantly increased, and complement C3 and haptoglobin were
similar in PD patients and controls.
Zhang et al. (2008) performed a proteomics-discovered multi-
analyte profile (MAP) in CSF on 95 control subjects, 48 patients
with probable AD, and 40 patients with probable PD, and con-
cluded that the optimal MAP leading to the correct diagnosis was
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composed of the following proteins in order of contribution: tau,
BDNF, IL-8, Aβ42, β2-microglobulin, vitamin D binding protein,
apoA2, and apoE.
Maarouf et al. (2012) analyzed ventricular CSF from PD and
controls obtained in the immediate post-mortem period using a
two-dimensional difference gel electrophoresis (2D-DIGE) cou-
pled with mass spectrophotometry protein identification, and
found differences between the 2 groups in 6 molecules: fibrino-
gen, transthyretin, apoE, clusterin, apoA1, and glutathione-S-
transferase-Pi (GSTP).
Trupp et al. (2014) reported a generally lower level of metabo-
lites in PD as compared to controls, with a specific decrease in
3-hydroxyisovaleric acid, tryptophan, and creatinine, a signifi-
cant decrease in the levels of Aβ-38 and Aβ-42, and an increase in
soluble amyloid peptide precursor α (APPα) in CSF of patients.
Ideally, future studies should fulfill the following conditions:
(a) a multicenter and prospective design; (b) inclusion of patients
diagnosed with PD and other types of parkinsonism according to
standardized criteria; (c) measurement of multiple potential bio-
logical markers in the CSF; (d) a very long-term follow-up period
(till death as end-point), with assessment of both clinical features
and serial determinations of the biological markers; and (e) final
neuropathological confirmation by examination of the brains of
patients at death (this is lacking in most of the studies published).
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